Skip to main content

Smiths Detection Wins NIH Grant for Flu Dx

NEW YORK (GenomeWeb News)— Smiths Detection has received a $2.2 million grant from the National Institutes of Health to develop a PCR-based test for multiple influenza types in humans, the London-based company said.

The two-year grant from the National Institute of Allergy and Infectious Diseases will support development of a test that will use LATE PCR technology on the company’s Bio-Seeq instrument and may be administered at the point of care or in a conventional lab.

Smiths Detection licensed the LATE PCR nucleic acid amplification technology from Brandeis University.

The firm also is developing a similar test for diagnosing influenza infections in animals that will use desktop and portable versions of the Bio-Seeq system.

"The pandemic influenza application makes excellent use of the full range of our diagnostic technologies, combining the need for a sophisticated highly multiplexed test with the need for rapid results at the point of care," Bill Mawer, who heads Smith Detections diagnostics business, said in a statement.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.